Amedeo Smart

Free Medical Literature Service

 

Amedeo

Genetics
  Free Subscription

Articles published in
Br J Cancer
    February 2024
  1. PRETE AA, Angerilli V, Bergamo F, Vettore V, et al
    HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-023-02569.
    >> Share

    January 2024
  2. WANG Y, He M, He T, Ouyang X, et al
    Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.
    Br J Cancer. 2024 Jan 22. doi: 10.1038/s41416-023-02555.
    >> Share

  3. HALLAL SM, Tuzesi A, Sida LA, Xian E, et al
    Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a 'liquid gold' biopsy.
    Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02548.
    >> Share

    December 2023
  4. GRASSMANN F, Malarstig A, Dahl L, Bendes A, et al
    The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.
    Br J Cancer. 2023 Dec 22. doi: 10.1038/s41416-023-02541.
    >> Share

    September 2023
  5. PAYNE K, Brooks J, Batis N, Khan N, et al
    Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.
    Br J Cancer. 2023 Sep 21. doi: 10.1038/s41416-023-02428.
    >> Share

  6. YANG Y, Xu S, Jia G, Yuan F, et al
    Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants.
    Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419.
    >> Share

  7. LIU Z, Duan T, Zhang Y, Weng S, et al
    Radiogenomics: a key component of precision cancer medicine.
    Br J Cancer. 2023;129:741-753.
    >> Share

    August 2023
  8. VAN MOURIK A, Tonkin-Hill G, O'Farrell J, Waller S, et al
    Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
    Br J Cancer. 2023;129:301-308.
    >> Share

    July 2023
  9. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    >> Share

    June 2023
  10. XU L, Su H, Zhao S, Si H, et al
    Development of the semi-dry dot-blot method for intraoperative detecting micropapillary component in lung adenocarcinoma based on proteomics analysis.
    Br J Cancer. 2023;128:2116-2125.
    >> Share

  11. KITAGAWA A, Osawa T, Noda M, Kobayashi Y, et al
    Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
    Br J Cancer. 2023;128:2206-2217.
    >> Share

    May 2023
  12. RASMUSSEN SV, Wozniak A, Lathara M, Goldenberg JM, et al
    Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma.
    Br J Cancer. 2023;128:1941-1954.
    >> Share

    April 2023
  13. ROSSWOG C, Fassunke J, Ernst A, Schomig-Markiefka B, et al
    Genomic ALK alterations in primary and relapsed neuroblastoma.
    Br J Cancer. 2023;128:1559-1571.
    >> Share

    March 2023
  14. CIFUENTES GA, Santiago A, Mendez Blanco L, Fueyo M, et al
    Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.
    Br J Cancer. 2023;128:857-876.
    >> Share

    February 2023
  15. NJOKU K, Pierce A, Geary B, Campbell AE, et al
    Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02139.
    >> Share

  16. CHEN G, Zhang J, Fu Q, Taly V, et al
    Integrative analysis of multi-omics data for liquid biopsy.
    Br J Cancer. 2023;128:505-518.
    >> Share

    December 2022
  17. ZHANG X, Yu Z, Xu Y, Chao Y, et al
    Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.
    Br J Cancer. 2022;127:2154-2165.
    >> Share

    November 2022
  18. NEUMANN O, Burn TC, Allgauer M, Ball M, et al
    Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
    Br J Cancer. 2022;127:1540-1549.
    >> Share

  19. HILTBRUNNER S, Fleischmann Z, Sokol ES, Zoche M, et al
    Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Br J Cancer. 2022;127:1997-2005.
    >> Share

    October 2022
  20. JAN YH, Tan KT, Chen SJ, Yip TTC, et al
    Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
    Br J Cancer. 2022;127:1304-1311.
    >> Share

    September 2022
  21. LI H, Sun Z, Xiao R, Qi Q, et al
    Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules.
    Br J Cancer. 2022;127:747-756.
    >> Share

  22. PRUIS MA, Groenendijk FH, Badloe KS, van Puffelen A, et al
    Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
    Br J Cancer. 2022;127:776-783.
    >> Share

    August 2022
  23. JUNG S, Armstrong E, Wei AZ, Ye F, et al
    Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01942.
    >> Share

  24. HSIEH CC, Hsu SH, Lin CY, Liaw HJ, et al
    CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01946.
    >> Share

  25. INGEBRIKTSEN LM, Finne K, Akslen LA, Wik E, et al
    A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01953.
    >> Share

    July 2022
  26. ROBINSON N, Casement J, Gunter MJ, Huybrechts I, et al
    Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors.
    Br J Cancer. 2022;127:288-300.
    >> Share

  27. GLEWIS S, Alexander M, Khabib MNH, Brennan A, et al
    A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
    Br J Cancer. 2022;127:126-136.
    >> Share

    June 2022
  28. CATANZARO D, Milani G, Bozza A, Bernardi M, et al
    Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01865.
    >> Share

    March 2022
  29. BOLGER JC, Donohoe CL, Lowery M, Reynolds JV, et al
    Advances in the curative management of oesophageal cancer.
    Br J Cancer. 2022;126:706-717.
    >> Share

    January 2022
  30. LAL N, Chan DKH, Ng ME, Vermeulen L, et al
    Primary tumour immune response and lymph node yields in colon cancer.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01700.
    >> Share

  31. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    >> Share

    December 2021
  32. ZHANG X, Li X, He Y, Law PJ, et al
    Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
    >> Share

    November 2021
  33. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
    Functional annotation of breast cancer risk loci: current progress and future directions.
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
    >> Share

  34. HAKOZAKI K, Tanaka N, Takamatsu K, Takahashi R, et al
    Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.
    Br J Cancer. 2021;125:1533-1543.
    >> Share

    September 2021
  35. CHEN D, Bao X, Zhang R, Ding Y, et al
    Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
    Br J Cancer. 2021;125:994-1002.
    >> Share

  36. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    >> Share

    August 2021
  37. GEVAERT O
    Meta-learning reduces the amount of data needed to build AI models in oncology.
    Br J Cancer. 2021;125:309-310.
    >> Share

    July 2021
  38. LEI JT, Zhang B
    Proteogenomics drives therapeutic hypothesis generation for precision oncology.
    Br J Cancer. 2021;125:1-3.
    >> Share

    June 2021
  39. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    >> Share

    May 2021
  40. SINGH G, Manjila S, Sakla N, True A, et al
    Radiomics and radiogenomics in gliomas: a contemporary update.
    Br J Cancer. 2021 May 6. pii: 10.1038/s41416-021-01387.
    >> Share

    February 2021
  41. ROSENTHAL R, Swanton C, McGranahan N
    Understanding the impact of immune-mediated selection on lung cancer evolution.
    Br J Cancer. 2021 Feb 24. pii: 10.1038/s41416-020-01232.
    >> Share

    January 2021
  42. BARROW TM, Nakjang S, Lafta F, Bilotkach K, et al
    Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
    Br J Cancer. 2021;124:474-483.
    >> Share

    October 2020
  43. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    >> Share

    July 2020
  44. HORNIGOLD N, Dunn KR, Craven RA, Zougman A, et al
    Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion.
    Br J Cancer. 2020;123:137-147.
    >> Share

    May 2020
  45. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    >> Share

    March 2020
  46. LUCA BA, Moulton V, Ellis C, Edwards DR, et al
    A novel stratification framework for predicting outcome in patients with prostate cancer.
    Br J Cancer. 2020 Mar 20. pii: 10.1038/s41416-020-0799.
    >> Share

  47. POWLEY IR, Patel M, Miles G, Pringle H, et al
    Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
    Br J Cancer. 2020;122:735-744.
    >> Share

    February 2020
  48. NIEGISCH G
    Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
    Br J Cancer. 2020;122:453-454.
    >> Share

  49. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
    Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Br J Cancer. 2020;122:382-387.
    >> Share

    January 2020
  50. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016